News Releases
In this section
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 5, 2020
Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 9,700,000 shares of its common stock at a price to the public of $23.25 per share....
-
May 4, 2020
Insmed Incorporated (Nasdaq: INSM) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Insmed intends to grant the...
-
Apr 30, 2020--Company Supports Investigator-Initiated Study of Brensocatib (Formerly INS1007) in Severe COVID-19 and Continues to Advance Development in Bronchiectasis--
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first...
-
Apr 23, 2020--Insmed to support STOP-COVID19 Study, Expected to Begin in the UK in May 2020--
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will provide funding...
-
Apr 20, 2020
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first...
-
Apr 3, 2020
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement...
-
Apr 2, 2020
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Carol A....
-
Mar 16, 2020-- Company Submits New Drug Application in Japan for ARIKAYCE® (amikacin liposome inhalation suspension) for the Treatment of Patients with NTM Lung Disease Caused by MAC --
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided a general business update....
-
Mar 5, 2020
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement...
-
Mar 4, 2020-- Management of common adverse events through physician-guided measures resulted in symptomatic improvement --
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced publication of results from a...
Contact Us
